share_log

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target

Benzinga ·  Sep 5, 2023 10:38

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment